# 2025年11月13日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 电阻抗断层成像技术引导分侧肺通气在局灶性ARDS中的应用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41222647](https://pubmed.ncbi.nlm.nih.gov/41222647)
**期刊：** Intensive care medicine
**PMID：** 41222647
**DOI：** 10.1007/s00134-025-08168-6

### 第一部分 原文与翻译

**英文原标题：** Electrical impedance tomography guided independent lung ventilation in focal ARDS.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究标题揭示了一项前沿的临床探索，其核心目的在于评估电阻抗断层成像（EIT）技术在引导局灶性急性呼吸窘迫综合征（ARDS）患者进行分侧肺通气（ILV）中的应用价值。通过利用EIT无创、实时的肺部通气分布监测能力，该方法有望为双肺病变严重不对称的患者实现更精准、个体化的呼吸支持，从而优化氧合并减少呼吸机相关的肺损伤。尽管缺乏摘要信息限制了我们对具体结果的了解，但该标题所展示的研究方向代表了重症呼吸治疗领域的一个重要创新，对于处理复杂ARDS病例具有显著的临床启示意义。

---

## 2. 2007-2019年创伤患者急性呼吸窘迫综合征：一项全面的患者及中心层面回顾性队列分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41222422](https://pubmed.ncbi.nlm.nih.gov/41222422)
**期刊：** Critical care medicine
**PMID：** 41222422
**DOI：** 10.1097/CCM.0000000000006936

### 第一部分 原文与翻译

**英文原标题：** Acute Respiratory Distress Syndrome in Trauma 2007-2019: Comprehensive Patient and Center-Level Retrospective Cohort Analysis.

**英文摘要原文：**
OBJECTIVES: Acute respiratory distress syndrome (ARDS) represents a significant complication in trauma patients. Yet the epidemiology of ARDS in trauma remains incompletely characterized. We sought to define trends in ARDS frequency and the effect of temporal, patient, and center-level factors on outcomes with the hypothesis that ARDS independently predicts mortality.

DESIGN: Retrospective cohort study.

SETTING: Hospitals submitting data to the American College of Surgeons National Trauma Data Bank.

PATIENTS: Injured patients 18 years old or older from 2007 to 2019 on mechanical ventilation (MV) for greater than or equal to 2 days were included, and patients with ARDS were compared with those without ARDS. A subgroup with transfusion data was also identified. Multivariable logistic regression models by year adjusted for patient demographics, center characteristics, and blood products identified factors independently associated with ARDS diagnosis and 30-day hospital mortality.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Of 384,032 injured patients on MV, ARDS was documented in 29,359 (8 per 100 MV patients) with a significant decrease over the study period (22 in 2007 vs. 3 in 2019, p < 0.001). Patient-level risk factors independently associated with ARDS were blunt injury (odds ratio [OR] 1.25; 95% CI, 1.20-1.30), severe sepsis (OR 2.16; 95% CI, 2.06-2.27), ventilator-associated pneumonia (OR 2.91; 95% CI, 2.82-3.00), and acute kidney injury (AKI, OR 2.98; 95% CI, 2.85 to 3.12). In the transfusion subset, 24-hour plasma (OR 1.02; 95% CI, 1.01-1.04) and platelets (OR 1.03; 95% CI, 1.02-1.05) were independently associated with ARDS. Crude ARDS mortality increased over the study period (2007, 15.1% vs. 2019, 29.7%, p < 0.001), and after adjusting for significant differences, ARDS was independently associated with 30-day hospital mortality (OR 1.32; 95% CI, 1.27-1.37). Independent risk factors for 30-day mortality in patients with ARDS included head injury (OR 1.54; 95% CI, 1.43-1.66), severe sepsis (OR 1.48; 95% CI, 1.34-1.63), and AKI (OR 2.72; 95% CI, 2.50-2.96). Patients with ARDS managed in Prevention and Early Treatment of Acute Lung Injury and the Extracorporeal Life Support Organization centers were less likely to die (OR 0.78; 95% CI, 0.72-0.84).

CONCLUSIONS: From 2007 to 2019, ARDS decreased significantly in trauma patients. Over the same time, mortality increased to nearly 30%, and after adjusting for other risks factors, ARDS was strongly associated with 30-day mortality. Future studies should examine modifiable patient and center-level factors to improve mortality in these high-risk patients.

**中文摘要译文：**
目的：急性呼吸窘迫综合征（ARDS）是创伤患者的一种严重并发症。然而，创伤中ARDS的流行病学特征仍未被完全阐明。我们旨在明确ARDS发生率的趋势以及时间、患者和中心层面因素对预后的影响，并假设ARDS是死亡率的独立预测因素。

设计：回顾性队列研究。

地点：向美国外科医师学会国家创伤数据库提交数据的医院。

患者：纳入2007年至2019年间年龄≥18岁、接受机械通气（MV）≥2天的受伤患者，并对患有ARDS的患者与未患ARDS的患者进行比较。同时，还识别了一个包含输血数据的亚组。通过按年份调整患者人口统计学、中心特征和血液制品的多变量逻辑回归模型，识别了与ARDS诊断和30天内住院死亡率独立相关的因素。

干预措施：无。

测量指标与主要结果：在384,032名接受MV的受伤患者中，有29,359名（每100名MV患者中8名）被记录患有ARDS，且在研究期间显著下降（2007年为22名 vs. 2019年为3名，p < 0.001）。与ARDS独立相关的患者层面风险因素包括钝性损伤（比值比[OR] 1.25；95% CI, 1.20-1.30）、严重脓毒症（OR 2.16；95% CI, 2.06-2.27）、呼吸机相关性肺炎（OR 2.91；95% CI, 2.82-3.00）和急性肾损伤（AKI, OR 2.98；95% CI, 2.85-3.12）。在输血亚组中，24小时内输注血浆（OR 1.02；95% CI, 1.01-1.04）和血小板（OR 1.03；95% CI, 1.02-1.05）与ARDS独立相关。研究期间，ARDS的粗死亡率有所上升（2007年为15.1% vs. 2019年为29.7%，p < 0.001），在调整了显著差异后，ARDS与30天内住院死亡率独立相关（OR 1.32；95% CI, 1.27-1.37）。ARDS患者30天死亡率的独立风险因素包括头部损伤（OR 1.54；95% CI, 1.43-1.66）、严重脓毒症（OR 1.48；95% CI, 1.34-1.63）和急性肾损伤（OR 2.72；95% CI, 2.50-2.96）。在“预防和早期治疗急性肺损伤网络”及“体外生命支持组织”中心接受治疗的ARDS患者死亡可能性较低（OR 0.78；95% CI, 0.72-0.84）。

结论：从2007年到2019年，创伤患者中ARDS的发生率显著下降。然而，同期死亡率却增至近30%，并且在调整其他风险因素后，ARDS与30天死亡率密切相关。未来的研究应着眼于可改变的患者及中心层面因素，以改善这些高危患者的死亡率。

### 第二部分 AI 大师评价

本研究基于美国国家创伤数据库，对2007至2019年间创伤患者并发ARDS的流行病学趋势及预后进行了大规模回顾性分析。其核心发现揭示了一个重要的矛盾现象：尽管创伤后ARDS的发生率显著下降，但一旦发生，其相关死亡率却近乎翻倍，凸显了临床管理的严峻挑战。该研究不仅明确了ARDS是死亡的独立危险因素，还识别了多个患者及中心层面的影响因子，为未来改善高危患者预后的研究指明了方向。此项大样本、长周期的分析对于重症创伤领域具有重要的警示价值和临床指导意义。

---

## 3. 重症监护室中疼痛、谵妄、精神障碍、不适及镇静镇痛管理的流行病学：一项为期一天的全国性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219892](https://pubmed.ncbi.nlm.nih.gov/41219892)
**期刊：** Critical care (London, England)
**PMID：** 41219892
**DOI：** 10.1186/s13054-025-05654-7

### 第一部分 原文与翻译

**英文原标题：** Epidemiology of pain, delirium, psychiatric disorders, discomfort and sedation-analgesia management in the intensive care unit: a one-day nationwide study.

**英文摘要原文：**
BACKGROUND: The administration of sedatives and analgesics in intensive care units (ICUs) has evolved significantly over the past 20 years, shifting from deep to light sedation strategies to minimize adverse effects. Despite this shift, substantial variability persists in sedation-analgesia practices. This study aimed to provide an updated national overview of sedation-analgesia management with a focus on discomfort assessment practices, including pain, delirium, anxiety, thirst, mood, and sleep disorders.

METHODS: This was a one-day, multicenter, cross-sectional study conducted in French ICUs. Data were collected from all adult patients hospitalized in the ICU on the study day. A Unit-level survey documented ICU characteristics and sedation-analgesia protocols. Patient-level data included sedation levels, pain scores, and assessments of discomfort conditions. Statistical analyses were performed using descriptive methods and multilevel logistic regression.

RESULTS: Among 258 French ICUs contacted, 128 units (50%) participated, enrolling 2,063 patients. Most ICUs were university-affiliated (54%) and mixed medical-surgical (58%); 63% had a written protocol for sedation-analgesia. Sedation and pain were assessed in 96% and 91% of ICUs, respectively. Light or no sedation was observed in 84% of patients, while 15% were deeply sedated - 63% of whom were misaligned with usual indications. Pain assessment was performed at rest in 90% of patients and during care in 62%. Pain prevalence increased with lighter sedation levels and during care. Hypnotics were used in 31% of patients, Mainly propofol and midazolam. Discomfort was reported in 44% of patients, mainly anxiety, sleep disorders, and thirst. Written protocols for sedation and analgesia were not associated with sedation depth, drug use, or delirium screening, but were linked to more frequent pain assessment at rest. Multivariable analyses showed that higher SOFA scores were associated with deep or misaligned deep sedation. The presence of a written protocol for sedation and analgesia reduced the risk of unassessed pain but was not associated with deep or misaligned deep sedation.

CONCLUSION: The shift toward lighter sedation has been successfully achieved; however, a broad spectrum of stressful symptoms persists, including pain, anxiety, thirst, and sleep disruption. These findings underscore the need for more effective strategies to optimize pain and overall patient comfort in non-deeply sedated ICU patients.

**中文摘要译文：**
背景：过去20年间，重症监护室（ICU）镇静剂和镇痛剂的使用发生了显著演变，策略已从深度镇静转向浅度镇静，以最大限度地减少不良反应。尽管存在这种转变，但镇静镇痛实践中仍然存在着显著的差异性。本研究旨在提供一份关于镇静镇痛管理的最新全国性概览，并重点关注不适症状的评估实践，包括疼痛、谵妄、焦虑、口渴、情绪和睡眠障碍。

方法：这是一项在法国ICU中进行的为期一天的多中心横断面研究。研究数据收集自研究当天所有在ICU住院的成年患者。一项在科室层面进行的调查记录了ICU的特征以及镇静镇痛方案。患者层面的数据包括镇静水平、疼痛评分以及不适状况的评估。统计分析采用描述性方法和多层次逻辑回归进行。

结果：在联系的258家法国ICU中，有128家（50%）参与了研究，共纳入2063名患者。大多数ICU为大学附属医院（54%）和综合性内外ICU（58%）；63%的ICU拥有书面的镇静镇痛方案。分别有96%和91%的ICU对镇静和疼痛进行了评估。84%的患者处于浅度镇静或无镇静状态，而15%的患者处于深度镇静状态——其中63%的患者与常规指征不符。90%的患者在静息状态下接受了疼痛评估，62%的患者在护理操作期间接受了疼痛评估。疼痛患病率随镇静水平变浅和在护理操作期间而增加。31%的患者使用了催眠药物，主要是丙泊酚和咪达唑仑。44%的患者报告了不适症状，主要包括焦虑、睡眠障碍和口渴。书面的镇静和镇痛方案与镇静深度、药物使用或谵妄筛查无相关性，但与更频繁地在静息状态下进行疼痛评估相关。多变量分析显示，较高的SOFA评分与深度镇静或不恰当的深度镇静相关。拥有书面的镇静和镇痛方案降低了疼痛未经评估的风险，但与深度镇静或不恰当的深度镇静无相关性。

结论：向浅度镇静的转变已成功实现；然而，包括疼痛、焦虑、口渴和睡眠中断在内的广泛应激性症状依然存在。这些发现强调，需要采取更有效的策略来优化非深度镇静ICU患者的疼痛管理和整体舒适度。

### 第二部分 AI 大师评价

本研究通过一项大规模的全国性横断面调查，精准描绘了法国ICU镇静镇痛及患者不适管理的现状。其核心发现揭示了一个重要的临床现实：尽管向浅度镇静的转变已基本成功，但疼痛、焦虑、睡眠障碍等不适症状在清醒患者中依然普遍存在，成为了新的管理挑战。该研究的价值在于，它量化了这一“后镇静时代”的问题，并指出仅有书面方案不足以改变实践核心。此发现有力地提示临床工作者和研究者必须将焦点从“如何减少镇静”转向“如何优化清醒患者的整体舒适度”。

---

## 4. 控制性机械通气与急性低氧性呼吸衰竭患者全身性炎症的关联：一项观察性队列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219816](https://pubmed.ncbi.nlm.nih.gov/41219816)
**期刊：** Critical care (London, England)
**PMID：** 41219816
**DOI：** 10.1186/s13054-025-05727-7

### 第一部分 原文与翻译

**英文原标题：** Association between controlled mechanical ventilation and systemic inflammation in acute hypoxemic respiratory failure: an observational cohort study.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究旨在通过一项观察性队列研究，探讨急性低氧性呼吸衰竭患者中，控制性机械通气与全身性炎症反应之间的关联。该研究切入点具有重要的临床意义，因为机械通气是治疗呼吸衰竭的关键手段，但其本身也可能加剧炎症反应，影响患者预后。由于缺乏摘要，本研究的具体发现、结论以及其创新性价值尚不明确，但该研究方向对于优化通气策略、减轻炎症损伤具有潜在的指导价值。

---

## 5. 皮质类固醇用于治疗急性呼吸窘迫综合征

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41218635](https://pubmed.ncbi.nlm.nih.gov/41218635)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41218635
**DOI：** 10.1055/a-2721-6094

### 第一部分 原文与翻译

**英文原标题：** Corticosteroids for Acute Respiratory Distress Syndrome.

**英文摘要原文：**
Acute respiratory distress syndrome (ARDS) remains a heterogeneous and a major challenge disease process despite five decades of study. Emerging translational data delineate three overlapping phases: exudative, proliferative, and fibroproliferative, each driven by distinct immune-mechanical pathways and potentially modifiable by glucocorticosteroids (GC) modulation. Contemporary clinical randomized trials and meta-analyses indicate that early (≤72 hours) administration of systemic GCs at receptor-saturating doses (e.g., dexamethasone from 20 to 10 mg/day, or methylprednisolone 1-2 mg/kg/day) accelerates resolution of pulmonary edema, shortens mechanical ventilation duration, and improves intensive care survival, while prolonged tapering regimens are required once fibroproliferation is established. Conversely, delayed initiation (>14 days), viral pneumonitis with high viral load, recent surgical anastomosis, or uncontrolled fungal coinfection constitute "red flags" in which GCs might increase mortality. Latent-class analyses-a statistical modeling approach in which multivariable data are reduced to indirectly observed (latent) variables-identified two (hyper- and hypoinflammatory) ARDS phenotypes that likely might respond differentially to GC exposure, although we lack validation studies. Therefore, it seems that biomarker-guided precision therapy is poised to replace the historical one-size-fits-all approach. This narrative review integrates epidemiology, pathobiology, pharmacology, and clinical evidence to provide a phase-specific, phenotype-directed framework for GC use in ARDS and outlines future research priorities aimed at harmonizing molecular endotyping with dose, timing, and tapering strategies.

**中文摘要译文：**
尽管经过了五十年的研究，急性呼吸窘迫综合征（ARDS）仍然是一种具有异质性的重大挑战性疾病。新兴的转化医学数据描绘了三个重叠的阶段：渗出期、增殖期和纤维增殖期，每个阶段都由独特的免疫-机械通路驱动，并可能通过糖皮质激素（GC）的调节而改变。当代的临床随机试验和荟萃分析表明，早期（≤72小时）以受体饱和剂量（例如，地塞米松20至10毫克/天，或甲基强的松龙1-2毫克/公斤/天）全身性应用糖皮质激素，可加速肺水肿的消退，缩短机械通气时间，并提高重症监护存活率，而一旦纤维增殖形成，则需要延长减量方案。相反，延迟启用（>14天）、高病毒载量的病毒性肺炎、近期手术吻合或未控制的真菌合并感染构成了“危险信号”，在这些情况下，糖皮质激素可能会增加死亡率。潜类别分析——一种将多变量数据简化为间接观察（潜伏）变量的统计建模方法——识别出两种（高炎症和低炎症）ARDS表型，它们对糖皮质激素的反应可能存在差异，尽管我们尚缺乏验证性研究。因此，生物标志物指导的精准治疗似乎有望取代历史上“一刀切”的治疗方法。这篇叙述性综述整合了流行病学、病理生物学、药理学和临床证据，为ARDS中糖皮质激素的使用提供了一个分阶段、表型导向的框架，并概述了未来旨在将分子内分型与剂量、时机和减量策略相协调的研究重点。

### 第二部分 AI 大师评价

该综述深刻总结了皮质类固醇在治疗急性呼吸窘迫综合征（ARDS）中的应用。文章整合了病理生理学、药理学及临床证据，创新性地提出了一个分阶段、表型导向的治疗框架，强调了早期、适量使用的益处与延迟或不当使用的风险。其核心价值在于倡导超越传统的“一刀切”模式，转向基于生物标志物的精准治疗，为临床决策提供了精辟的指导，并为未来的分子分型研究指明了方向。

---

## 6. 弥漫性肺泡出血。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41130281](https://pubmed.ncbi.nlm.nih.gov/41130281)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41130281
**DOI：** 10.1055/a-2725-7274

### 第一部分 原文与翻译

**英文原标题：** Diffuse Alveolar Hemorrhage.

**英文摘要原文：**
Diffuse alveolar hemorrhage (DAH) is a life-threatening clinical syndrome characterized by bleeding from the pulmonary microcirculation into alveolar spaces. It typically presents with acute respiratory failure, anemia, and diffuse radiological infiltrates. Importantly hemoptysis may be absent in up to half of cases. Etiologies are diverse, encompassing systemic vasculitides, connective tissue diseases, coagulopathies, drugs, infections, hemodynamic disturbances, and idiopathic processes. Histopathologically, DAH manifests as one of three overlapping patterns: pulmonary capillaritis, bland alveolar hemorrhage, or diffuse alveolar damage, which help guide diagnostic and therapeutic strategies. Capillaritis, commonly associated with immune-mediated vasculitis such as antineutrophil cytoplasmic antibody-associated vasculitis and anti-glomerular basement membrane disease, typically necessitating prompt and aggressive immunosuppression. In contrast, bland hemorrhage often reflects coagulopathy or hemodynamic factors, whereas diffuse alveolar damage is linked to toxins, infections, or acute respiratory distress syndrome. Prompt recognition and systematic evaluation are critical to optimizing outcomes, given DAH's high in-hospital mortality exceeding 20%. Diagnosis relies on a combination of imaging, bronchoalveolar lavage (demonstrating progressively bloodier returns and hemosiderin-laden macrophages), and targeted laboratory evaluation for vasculitis, infection, and coagulopathy. Management includes patient stabilization with supplementary oxygen or indeed ventilatory support, careful avoidance of ventilator-induced lung injury, and etiology-directed therapy. High-dose corticosteroids, cytotoxic agents, and rituximab remain central in immune-mediated cases, whereas plasma exchange is indicated in anti-glomerular basement membrane disease and severe refractory hemoptysis. Antimicrobial therapy, drug withdrawal, hemostatic interventions, and, in select cases, extracorporeal support may also be required. This review outlines the histopathological spectrum, etiologic categories, diagnostic algorithms, and evidence-based therapeutic approaches to DAH, emphasizing the importance of early multidisciplinary management to improve survival and functional recovery.

**中文摘要译文：**
弥漫性肺泡出血（DAH）是一种危及生命的临床综合征，其特征是肺部微循环出血并进入肺泡腔。其典型表现为急性呼吸衰竭、贫血和弥漫性影像学浸润。重要的是，高达半数的病例可能没有咯血症状。其病因多样，包括系统性血管炎、结缔组织病、凝血功能障碍、药物、感染、血流动力学紊乱和特发性病变。在组织病理学上，DAH表现为三种重叠模式之一：肺毛细血管炎、单纯性肺泡出血或弥漫性肺泡损伤，这有助于指导诊断和治疗策略。肺毛细血管炎通常与免疫介导的血管炎（如抗中性粒细胞胞浆抗体相关性血管炎和抗肾小球基底膜病）相关，通常需要迅速且积极的免疫抑制治疗。相比之下，单纯性出血通常反映了凝血功能障碍或血流动力学因素，而弥漫性肺泡损伤则与毒素、感染或急性呼吸窘迫综合征有关。鉴于DAH的院内死亡率超过20%，及时识别和系统性评估对于优化预后至关重要。诊断依赖于影像学、支气管肺泡灌洗（显示灌洗液血性程度递增和含铁血黄素的巨噬细胞）以及针对血管炎、感染和凝血功能的靶向实验室检查的结合。治疗措施包括通过吸氧或呼吸机支持来稳定患者生命体征，谨慎避免呼吸机相关性肺损伤，并进行针对病因的治疗。大剂量皮质类固醇、细胞毒性药物和利妥昔单抗在免疫介导的病例中仍是核心治疗方法，而血浆置换则适用于抗肾小球基底膜病和严重的难治性咯血。在特定情况下，可能还需要抗微生物治疗、停用相关药物、止血干预以及体外生命支持。这篇综述概述了DAH的组织病理学谱系、病因分类、诊断流程和循证治疗方法，强调了早期多学科管理对于提高生存率和促进功能恢复的重要性。

### 第二部分 AI 大师评价

该文献是一篇关于弥漫性肺泡出血（DAH）的全面综述，旨在系统性地阐述这一危重症的病理学特征、多样的病因、诊断流程及治疗策略。文章核心总结了DAH的三种组织病理学模式，并以此为基础，将诊断与病因（如免疫性疾病、凝血障碍等）及相应的治疗方案（如免疫抑制、血浆置换）紧密联系起来。作为一篇指导性文献，其临床价值极高，为呼吸与危重症医学科医生快速识别和处理DAH提供了清晰的循证框架，并通过强调早期多学科管理的重要性，对改善这一高死亡率综合征的患者预后具有重要的实践指导意义。

---

速递结束，祝您工作愉快！